id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-N-2980-0006,FDA,FDA-2024-N-2980,"Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-On Recombinant Peptide Products;
Reopening of the Comment Period",Notice,Extension of Comment Period,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T14:48:35Z,2024-31365,0,0,0900006486896ad4
FDA-2024-N-2980-0001,FDA,FDA-2024-N-2980,"Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-On Recombinant Peptide Products;
Establishment of a Public Docket; Request for Information and Comments",Notice,Request for Comments,2024-07-25T04:00:00Z,2024,7,2024-07-25T04:00:00Z,2025-03-04T04:59:59Z,2025-03-05T02:00:37Z,2024-16356,0,0,0900006486605081